- Home
- BIIB vs TYL Comparison
BIIB vs TYL Comparison
Compare BIIB & TYL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- TYL
- Stock Information
- Founded
- BIIB 1978
- TYL 1966
- Country
- BIIB United States
- TYL United States
- Employees
- BIIB N/A
- TYL N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- TYL Computer Software: Prepackaged Software
- Sector
- BIIB Health Care
- TYL Technology
- Exchange
- BIIB Nasdaq
- TYL Nasdaq
- Market Cap
- BIIB 18.7B
- TYL 21.6B
- IPO Year
- BIIB 1991
- TYL N/A
- Fundamental
- Price
- BIIB $146.19
- TYL $513.28
- Analyst Decision
- BIIB Buy
- TYL Buy
- Analyst Count
- BIIB 25
- TYL 11
- Target Price
- BIIB $183.05
- TYL $686.00
- AVG Volume (30 Days)
- BIIB 1.7M
- TYL 351.0K
- Earning Date
- BIIB 10-30-2025
- TYL 10-29-2025
- Dividend Yield
- BIIB N/A
- TYL N/A
- EPS Growth
- BIIB 31.67
- TYL 44.59
- EPS
- BIIB 10.45
- TYL 6.99
- Revenue
- BIIB $9,997,000,000.00
- TYL $2,245,750,000.00
- Revenue This Year
- BIIB $2.00
- TYL $10.77
- Revenue Next Year
- BIIB N/A
- TYL $9.33
- P/E Ratio
- BIIB $13.68
- TYL $72.33
- Revenue Growth
- BIIB 3.36
- TYL 10.69
- 52 Week Low
- BIIB $110.04
- TYL $483.56
- 52 Week High
- BIIB $191.19
- TYL $661.31
- Technical
- Relative Strength Index (RSI)
- BIIB 53.14
- TYL 47.33
- Support Level
- BIIB $141.70
- TYL $495.53
- Resistance Level
- BIIB $147.48
- TYL $511.87
- Average True Range (ATR)
- BIIB 4.84
- TYL 13.18
- MACD
- BIIB -1.02
- TYL 2.11
- Stochastic Oscillator
- BIIB 27.03
- TYL 71.61
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About TYL Tyler Technologies Inc.
Tyler Technologies provides a full suite of software solutions and services that address the needs of cities, counties, schools, courts and other local government entities. The company's three core products are Munis, which is the core ERP system, Odyssey, which is the court management system, or CMS, and payments. The company also provides a variety of add-on modules and offers outsourced property tax assessment services.